Literature DB >> 24780816

Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype.

Lijun Zhang1, Detlef Schuppan2.   

Abstract

Entities:  

Keywords:  Antifibrotic; Cirrhosis; Collagen; Fibrosis; HBV; HCV; Hepatitis; Herb; Inflammation; Liver; NASH; TCM

Mesh：

Substances：

Year:  2014        PMID： 24780816     DOI： 10.1016/j.jhep.2014.03.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  27 in total

1.  Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation.

Authors:  Tingting Yan; Hong Wang; Lijuan Cao; Qiong Wang; Shogo Takahashi; Tomoki Yagai; Guolin Li; Kristopher W Krausz; Guangji Wang; Frank J Gonzalez; Haiping Hao
Journal:  Drug Metab Dispos       Date:  2018-06-29       Impact factor: 3.922

2.  A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo.

Authors:  Tao Guo; Zu-Long Liu; Qiang Zhao; Zhi-Min Zhao; Cheng-Hai Liu
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

3.  Salvianolic Acid B Enhances Hepatic Differentiation of Human Embryonic Stem Cells Through Upregulation of WNT Pathway and Inhibition of Notch Pathway.

Authors:  Jiamei Chen; Benjamin Tschudy-Seney; Xiaocui Ma; Mark A Zern; Ping Liu; Yuyou Duan
Journal:  Stem Cells Dev       Date:  2018-01-23       Impact factor: 3.272

4.  Glycyrrhizin Protects against Acetaminophen-Induced Acute Liver Injury via Alleviating Tumor Necrosis Factor α-Mediated Apoptosis.

Authors:  Tingting Yan; Hong Wang; Min Zhao; Tomoki Yagai; Yingying Chai; Kristopher W Krausz; Cen Xie; Xuefang Cheng; Jun Zhang; Yuan Che; Feiyan Li; Yuzheng Wu; Chad N Brocker; Frank J Gonzalez; Guangji Wang; Haiping Hao
Journal:  Drug Metab Dispos       Date:  2016-03-10       Impact factor: 3.922

5.  [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study].

Authors:  Yuchen Zhou; Chengguang Hu; Guosheng Yuan; Junwei Liu; Yanyu Ren; Cuirong Tang; Shuling Yang; Lin Dai; Yuan Li; Dinghua Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-06-30

Review 6.  Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.

Authors:  Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-01-07       Impact factor: 5.810

Review 7.  Better plans and more powerful evidence are needed in the research and treatment of chronic hepatitis B in China.

Authors:  Changtai Zhu; Yulu Gao; Lihui Jiang; Baoqiong Ding; Yongning Sun
Journal:  Int J Clin Exp Med       Date:  2015-12-15

8.  Minimal Hepatic Encephalopathy and Biejia-Ruangan Are Associated with First Hospital Readmission in Nonalcoholic Cirrhosis Patients.

Authors:  Ting-Ting Jiang; Xiao-Li Liu; Yu-Yong Jiang; Xian-Bo Wang; Zhi-Yun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-07       Impact factor: 2.629

9.  Salidroside Modulates Insulin Signaling in a Rat Model of Nonalcoholic Steatohepatitis.

Authors:  Hongshan Li; Hao Ying; Airong Hu; Dezhou Li; Yaoren Hu
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-01       Impact factor: 2.629

10.  Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu.

Authors:  Jiamei Chen; Wei Gao; Ping Zhou; Xiaocui Ma; Benjamin Tschudy-Seney; Chenghai Liu; Mark A Zern; Ping Liu; Yuyou Duan
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.